India’s pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which increased sales by 19% and 17% respectively, liver therapies, Liv-52 by 17%, and Udiliv 28%.
